Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell disease
Pharma
Agios’ Pyrukynd turns in mixed results in sickle cell ph. 3
Agios’ shares nosedived by 49% on Wednesday morning after the company revealed mixed phase 3 results for Pyrukynd in sickle cell disease.
Zoey Becker
Nov 19, 2025 12:00pm
Pfizer debuts video series about life with sickle cell disease
Jun 9, 2025 1:25pm
Amid ongoing launches, Novo eyes rare disease leadership
Mar 7, 2025 9:20am
Pfizer pulls sickle cell disease drug Oxbryta from global markets
Sep 25, 2024 6:00pm
New York hospital creates basketball for sickle cell push
Sep 10, 2024 11:51am
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Aug 14, 2024 12:07pm
